Neutral metoclopramide sensitizes cytotoxicity induced by ionizing radiation in scid mice xenografted with a human brain astrocytoma

International Journal of Cancer

Volumn 73, Issue 6, 1997, Pages 871-874

  Hua, Jianyi ^a   Olsson, Anders R ^a   Pero, Ronald W ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

METOCLOPRAMIDE; RADIOSENSITIZING AGENT;

ANIMAL; ARTICLE; ASTROCYTOMA; BLOOD BRAIN BARRIER; BODY WEIGHT; BRAIN; CANCER TRANSPLANTATION; CELL CULTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; METABOLISM; MOUSE; MOUSE MUTANT; MULTIMODALITY CANCER THERAPY;

ANIMALS; ASTROCYTOMA; BLOOD-BRAIN BARRIER; BODY WEIGHT; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMBINED MODALITY THERAPY; HUMANS; MALE; METOCLOPRAMIDE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED;

EID: 0031564176     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19971210)73:6<871::AID-IJC18>3.0.CO;2-7     Document Type: Article

References (19)

1. ATTIA, M.A. and WEISS, D.W., Immunology of spontaneous mammary carcinomas in mice. V. Acquired tumor resistance and enhancement in strain-A mice infected with mammary tumor virus. Cancer Res., 26, 1787-800 (1966).
2. GREEN, S.B., BYAR, D.P. and WALKER, M.D., Comparisons of carmustine, procarbazine, and high-dose methyl-prednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat. Rep., 67, 121-132 (1983).
3. HARRINGTOM, R.A., HAMILTON, C.W., BROGBEN, R.N., LINKEWICH, J.A., ROMANKIEWICZ, J.A. and HEEL, R.C., Metoclopramide. An updated review of its pharmacological properties and clinical use. Drugs, 25, 451-549 (1983).
4. HUA, J., OLSSON, A., SHENG, Y. and PERO, R.W., Acidic and neutralized metoclopramide formulations sensitize ionizing-radiation-induced cytotoxicity in a human lung adenocarcinoma xenografted to SCID mice. Anti-Cancer Drugs, 6, 451-455 (1995).
5. JOHNSSON, A., KJELLÉN, E., WENNERBERG, J. and PERO, R.W., Metoclopramide as a modulator of cisplatin: effects on pharmacokinetics and cisplatin-DNA adducts in tumor and normal tissue. Anti-cancer Drugs, 7, 483-488 (1996).
6. 3 receptor antagonists. Drugs of the Future, 14, 1419-1424 (1989).
7. KJELLÉN, E., PERO, R.W., BRUN, E., EWERS, S.B., JARLMAN, O., KNÖÖS, T., MALMSTRÖM, P., TENNVALL, J., KILLANDER, D., OLSSON, A., SHENG, Y. and WENNERBERG, J., A phase-I/II evaluation of metoclopramide as a radiosensitiser in patients with inoperable squamous-cell carcinoma of the lung. Europ. J. Cancer, 31, 2196-2202 (1995).
8. KJELLÉN, E., WENNERBERG, J. and PERO, R.W., Metoclopramide enhances the effect of cisplatin on xenografted squamous-cell carcinoma of the head and neck. Brit. J. Cancer, 59, 247-250 (1989).
9. LESSER, M.L., BRAUN, H.L. and HELSON, L., Statistical methods for measuring and comparing treatment efficacies: application to nude-mice experiment. Exp. Cell Biol., 48, 126-137 (1980).
10. LYBAK, S., KJELLÉN, E., NILSSON, P., TOMASZEWICZ, A., WENNERBERG, J. and PERO, R.W., Normal tissue reactions and optimization of dose schedule for metoclopramide in combination with ionizing radiation. Acta oncol., 31, 469-474 (1992).
11. LYBAK, S., KJKLLÉN, E., WENNERBERG, J. and PERO, R.W., Metoclopramide enhances the effect of ionizing radiation on xenografted squamous-cell carcinoma of the head and neck. Int. J. Rad. Onc. Biol. Phys., 19, 1419-1424 (1990).
12. LYBAK, S., WENNERBERG, J., KJELLÉN. E. and PERO, R.W., Dose-schedule evaluation of metoclopramide as a potentiator of cisplatin and carboplatin treatments of xenografted squamous-cell carcinomas of the head and neck. Anti-Cancer Drugs, 2, 375-382 (1991).
13. OLSSON, A., HUA, J., SHENG, Y. and PERO, R.W., Neutral metoclopramide induces tumor cytotoxicity and sensitizes ionizing radiation of a human lung and an adeno-type-12-virus-induced mouse sarcoma in mice. Acta oncol., 36, 321-328 (1997).
14. OLSSON, A., SHENG, Y., KJELLÉN, E. and PERO, R.W., In vivo tumor measurement of DNA damage. DNA repair and NAD pools as indicators of radiosensitization by metoclopramide. Carcinogenesis, 16, 1029-1035 (1996).
15. PERO, R.W., OLSSON, A., SHENG, Y., HUA, J., MÖLLER, C., KJELLÉN, E., KILLANDER, D. and MARMOR, M.M., Progress in identifying clinical relevance of inhibition, stimulation and measurement of poly ADP-ribosylation. Biochimie, 77, 385-393 (1995).
16. PERO, R.W., OLSSON, A., SIMANAITIS, M., AMIRI, A. and ANDERSEN, I., Pharmacokinetics, toxicity, side effects, receptor affinities and in vitro radiosensitizing effects of the novel metoclopramide formulations, Sensamide and Neu-Sensamide. Pharmacol. Toxicol., 80, 231-239 (1997).
17. ROTMENSCH, H.H., MAU, L.D., SATTON, J.A., KILMINSTER, S.S., MÖLLER, C. and PERO, R.W., Comparative central neurons system effects and pharmacokinetics of Neu-Sensamide and Metoclopramide in healthy volunteers. J. clin. Pharmacol., 34, 222-228 (1997).
18. ROTROSEN, J., STANLEY, M., LAUTIN, A., WAZER, D. and GERSHON, S., Discrimination of functionally heterogeneous receptor sub-populations: antipsychotic and antidopaminergic properties of metoclopramide. Psychopharmacol. Bull., 17, 110-113 (1981).
19. SALFORD, L.G., PERO, R.W., AAS, A.T. and BRUN, A., Metoclopramide as a sensitizer of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) treatment of brain tumors in the rat. Anti-Cancer Drugs, 3, 267-272 (1992).